Tiny trial tests vasopressin to save Newborns' hearts
NCT ID NCT05738148
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares vasopressin to the standard drug epinephrine for newborns who need CPR at birth. Only 8 babies were enrolled, and the hospital was randomly assigned to use one drug for a year. The goal is to see which drug helps restart the heart faster, but the results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vasopressin
- What this could lead to
- If vasopressin works better than epinephrine, it could offer a new option to restart a newborn's heart during CPR.
- What could go wrong
- This is a tiny phase 1 trial with only 8 babies, so it cannot prove safety or effectiveness. The results may not apply to all newborns.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC ARREST NEONATAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Royal Alexandra Hospital
Edmonton, Alberta, T5H 3V9, Canada